Lyme C6 peptidetest Lyme disease, a tick-borne illness caused by Borrelia burgdorferi, presents a diagnostic challenge due to its varied and often non-specific symptoms. The C6 Lyme peptide ELISA has emerged as a significant advancement in the serological diagnosis of this complex condition. This article delves into the science behind the C6 peptide ELISA, its role in Lyme disease detection, and the evidence supporting its efficacy.
The C6 peptide itself is a crucial component. It is a synthetic peptide derived from the VlsE surface protein of Borrelia burgdorferilyme disease c6 peptide by elisa (mdl) - Health Lab. This peptide is highly conserved across different strains of the bacteria, making it a reliable target for antibody detection.VlsE C6 peptide and IgG ELISA antibody analysis... The development of the C6 Lyme peptide ELISA utilized this recombinant protein antigen (peptide C6), marking a significant step forward from earlier diagnostic methods.Single-tier testing with the C6 peptide ELISA kit compared ...
The C6 Lyme peptide ELISA (Enzyme-Linked Immunosorbent Assay) is designed to detect the presence of antibodies against the C6 peptide in a patient's serum. This is achieved by coating microplate wells with the C6 peptide.作者:AR Marques·2002·被引用次数:49—The C6 peptide ELISAcan be used to diagnose Lyme diseasein patients who have received the OspA vaccine. Lyme disease (LD) is the most common vector-borne ... If antibodies specific to this peptide are present in the patient's blood sample, they will bind to the immobilized C6 peptide. A secondary antibody, conjugated to an enzyme, is then added. This secondary antibody binds to the patient's antibodies. Finally, a substrate is added, which reacts with the enzyme to produce a color change. The intensity of the color is directly proportional to the amount of C6 antibodies present, allowing for a quantifiable result.
This ELISA format allows for the detection of both IgG and IgM antibodies against the C6 peptide, providing valuable information about both recent and past infections作者:VG Pomelova·2015·被引用次数:23—Single-tier testing with the C6 peptide ELISA kitcompared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis. 2013; 75(1): 9–15. doi .... The B. burgdorferi (Lyme) ELISA kit based on this principle offers a "quantum leap forward in accuracy," according to some studies.
The C6 Lyme peptide ELISA has demonstrated high sensitivity and specificity in numerous studies, making it a valuable diagnostic tool作者:I Christova·2013·被引用次数:10—This study showed thatC6 peptidescan be used successfully for diagnosis, since up to 80% of the patients with earlyLymeborreliosis and .... Research has shown that the C6 ELISA can be used as a first-line test or as a second-tier confirmatory test in a two-tiered diagnostic scheme for Lyme borreliosis.Seroreactivity to the C6 Peptide in Borrelia miyamotoi ...
One of the key advantages of the C6 peptide test is its ability to diagnose Lyme disease even in patients who have received the OspA vaccine. Unlike earlier tests, antibodies generated from OspA vaccination do not cross-react with the C6 peptide, meaning a positive C6 test indicates a natural infection rather than a vaccine response. This is because antibodies to the C6 peptide are an indication of natural infection.
Furthermore, studies have indicated that single-tier testing with the C6 peptide ELISA kit can provide increased sensitivity in early Lyme disease compared to traditional two-tier testing, while maintaining comparable sensitivity in later stages of the illness. The performance evaluation of the C6 Lyme ELISA kit has been a subject of ongoing research, with multicenter evaluations aiming to standardize its use.Multicenter Evaluation of the C6 Lyme ELISA Kit for ...
The C6 Lyme ELISA is also being explored for its potential in diagnosing other tick-borne illnesses. Some research suggests that the C6 peptide test used to diagnose Lyme disease may also be helpful in identifying Borrelia miyamotoi infection.作者:ND van Burgel·2011·被引用次数:37—With the optimal cut-off of 1.1, the sensitivity of theC6-peptide ELISAfor LNB patients in CSF was 95%, and the specificity was 83% in the ...
The scientific literature is rich with studies evaluating the C6 Lyme peptide ELISAHigh sensitivity and specificity of the C6-peptide ELISA on .... For instance, research by Tjernberg et al. (2007) highlighted the utility of the C6 peptide ELISA test in the serodiagnosis of Lyme and noted that a positive C6 test correlates well with acute borreliosis, with lower cross-reactivity in sera positive for other infections like Epstein-Barr virus. Nyman et al.TL;DR: Using a reference standard of 2-tier testing, theC6 ELISAas a single-step serodiagnostic test provided increased sensitivity in earlyLymedisease ... (2006) demonstrated that an ELISA for VlsE C6 peptide antibodies could replace immunoblotting as a confirmatory test for Lyme borreliosis.Immunetics introduces a newB. burgdorferi (Lyme) ELISA kitbased on the C6 peptide of the VlsE protein, offering a quantum leap forward in accuracy.
Van Burgel et al. (2011) reported high sensitivity and specificity for the C6-peptide ELISA, with a sensitivity of 95% and specificity of 83% for Lyme neuroborreliosis (LNB) patients in cerebrospinal fluid (CSF) at an optimal cut-off of 1.1. Marques et al. (2002) also emphasized the C6 peptide ELISA's ability to diagnose Lyme disease in vaccinated individualsSingle-tier testing with the C6 peptide ELISA kit compared ....
While the C6 ELISA offers significant advantages, it's important to note that its role can varyC6 Peptide-Based Multiplex Phosphorescence Analysis .... In some contexts, when the C6 peptide EIA is used as the second-tier test, it should be regarded as a supplemental rather than a purely confirmatory test, as indicated by Wormser et al. (2018).VlsE C6 peptide and IgG ELISA antibody analysis for ... Nevertheless, its ability to detect antibodies against the C6 peptide, which is a key antigenic determinant of Borrelia burgdorferi, makes it an indispensable tool in the ongoing effort to accurately diagnose and manage Lyme disease.This ELISA detects both IgG and IgM antibodies against the C6 peptidederived from the V1sE protein of Borrelia burgdorferi, the causative agent of Lyme disease ... The development of the C6 Lyme ELISA represents a significant stride in understanding and combating this prevalent infectious disease.
Join the newsletter to receive news, updates, new products and freebies in your inbox.